Biological Cost of Helicobacter pylori Rifampicin Resistance

The frequence of mutations in the rifampicin resistant (RIFr) clones of microorganisms after adaption to ofloxacin and metronidazole was investigated to estimate the biological cost of H.pylori rifampicin (RIF) resistance. Mutations in rpoB gene responsible for RIF resistance of H.pylori were shown...

Full description

Saved in:
Bibliographic Details
Main Authors: K. T. Momynaliev, V. V. Chelysheva, T. A. Akopian, O. V. Selezneva, V. M. Govorun
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2020-05-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/258
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849692802464612352
author K. T. Momynaliev
V. V. Chelysheva
T. A. Akopian
O. V. Selezneva
V. M. Govorun
author_facet K. T. Momynaliev
V. V. Chelysheva
T. A. Akopian
O. V. Selezneva
V. M. Govorun
author_sort K. T. Momynaliev
collection DOAJ
description The frequence of mutations in the rifampicin resistant (RIFr) clones of microorganisms after adaption to ofloxacin and metronidazole was investigated to estimate the biological cost of H.pylori rifampicin (RIF) resistance. Mutations in rpoB gene responsible for RIF resistance of H.pylori were shown to have biological cost and be compensated by additional mutations in the microorganism genome. Comparison of the mutation frequency in the presence of metroniazole demonstrated that the acquired resistance to RIF resulted in changing of the adaptative capacity of the RIFr clones of H.pylori to metronidazole. Thus, a significant increase of the mutation frequency (> 700 times) in one of the RIFr clones and a broad spectrum of the mutations responsible for resistance to metronidazole vs. the H.pylori initial strain 26695 were observed. The findings could be evident of the fact that the adaptation to RIF changed the properties of the cell on one hand in such a way that its mutation capacity increased and that the target selection on the other hand revealed hypermutable cells, likely usual for the bacterial population.
format Article
id doaj-art-43f158fcbc2044b5987da58fd4ff8584
institution DOAJ
issn 0235-2990
language Russian
publishDate 2020-05-01
publisher LLC "Publishing House OKI"
record_format Article
series Антибиотики и Химиотерапия
spelling doaj-art-43f158fcbc2044b5987da58fd4ff85842025-08-20T03:20:37ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902020-05-01549-101015257Biological Cost of Helicobacter pylori Rifampicin ResistanceK. T. Momynaliev0V. V. Chelysheva1T. A. Akopian2O. V. Selezneva3V. M. Govorun4Research Institute of Physico-Chemical Medicine, MoscowResearch Institute of Physico-Chemical Medicine, MoscowResearch Institute of Physico-Chemical Medicine, MoscowResearch Institute of Physico-Chemical Medicine, MoscowResearch Institute of Physico-Chemical Medicine, MoscowThe frequence of mutations in the rifampicin resistant (RIFr) clones of microorganisms after adaption to ofloxacin and metronidazole was investigated to estimate the biological cost of H.pylori rifampicin (RIF) resistance. Mutations in rpoB gene responsible for RIF resistance of H.pylori were shown to have biological cost and be compensated by additional mutations in the microorganism genome. Comparison of the mutation frequency in the presence of metroniazole demonstrated that the acquired resistance to RIF resulted in changing of the adaptative capacity of the RIFr clones of H.pylori to metronidazole. Thus, a significant increase of the mutation frequency (> 700 times) in one of the RIFr clones and a broad spectrum of the mutations responsible for resistance to metronidazole vs. the H.pylori initial strain 26695 were observed. The findings could be evident of the fact that the adaptation to RIF changed the properties of the cell on one hand in such a way that its mutation capacity increased and that the target selection on the other hand revealed hypermutable cells, likely usual for the bacterial population.https://www.antibiotics-chemotherapy.ru/jour/article/view/258helicobacter pylorihelicobacter pyloririfampicin resistancetarget selectionofloxacinmetronidazole
spellingShingle K. T. Momynaliev
V. V. Chelysheva
T. A. Akopian
O. V. Selezneva
V. M. Govorun
Biological Cost of Helicobacter pylori Rifampicin Resistance
Антибиотики и Химиотерапия
helicobacter pylori
helicobacter pylori
rifampicin resistance
target selection
ofloxacin
metronidazole
title Biological Cost of Helicobacter pylori Rifampicin Resistance
title_full Biological Cost of Helicobacter pylori Rifampicin Resistance
title_fullStr Biological Cost of Helicobacter pylori Rifampicin Resistance
title_full_unstemmed Biological Cost of Helicobacter pylori Rifampicin Resistance
title_short Biological Cost of Helicobacter pylori Rifampicin Resistance
title_sort biological cost of helicobacter pylori rifampicin resistance
topic helicobacter pylori
helicobacter pylori
rifampicin resistance
target selection
ofloxacin
metronidazole
url https://www.antibiotics-chemotherapy.ru/jour/article/view/258
work_keys_str_mv AT ktmomynaliev biologicalcostofhelicobacterpyloririfampicinresistance
AT vvchelysheva biologicalcostofhelicobacterpyloririfampicinresistance
AT taakopian biologicalcostofhelicobacterpyloririfampicinresistance
AT ovselezneva biologicalcostofhelicobacterpyloririfampicinresistance
AT vmgovorun biologicalcostofhelicobacterpyloririfampicinresistance